Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Rhone Poulenc Plunges Into Biotech


In Business This Week

RHONE-POULENC PLUNGES INTO BIOTECH

Pharmaceutical outfit Rhone-Poulenc Rorer will boost development of gene and cell therapies when it takes a controlling stake in Applied Immune Sciences, a cell-therapy pioneer. RPR was scheduled to announce on June 3 that it plans to invest $113 million in the nine-year-old Santa Clara (Calif.) company for a 37% interest. RPR's holdings could grow to 60% by the middle of 1997. The companies hope to jointly open cell-therapy centers worldwide, using techniques developed by Applied Immune that are still in clinical testing and not yet approved by U. S. regulators. One promising technique: taking blood or bone-marrow cells from cancer and AIDS patients, treating them, and then reinfusing them in the patients to restore health.EDITED BY JULIE TILSNER


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus